ArticleImmunologic research2025
Post-COVID-19 era sero-surveillance of anti-measles IgM and IgG antibodies among asymptomatic Tanzanian children aged 3 to 15 years Journal.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
In July 2022, during the COVID-19 era, Tanzania reported over 1500 laboratory-confirmed measles cases and more than 30 deaths, with about 80% of the children not vaccinated. The response was an intensive vaccination campaign that targeted under-fives across the country. This was a cross-sectional measles-serosurveillance study conducted in 2024, after the COVID-19 era, in Dar es Salaam. The study involved children aged 3 to 15 years who were attending Temeke Regional Referral Hospital (TRRH) in Dar es Salaam, Tanzania, during the study period. Children were screened for anti-measles IgM and IgG antibodies using the NovaLisa Measles ELISA kit (NovaTec Immunodiagnostica GmbH® kit) and were categorized into four groups: (i) immune to measles (presence of anti-measles virus IgG and absence of anti-measles virus IgM), (ii) having reactivated measles (presence of both anti-measles virus IgG and anti-measles virus IgM), (iii) recently contracted measles (absence of anti-measles virus IgG and presence of IgM), and (iv) vulnerable (absence of both anti-measles virus IgG and anti-measles virus IgM). Of the 155 collected blood samples, 32 (20.64%) were positive for IgM, 35 (22.58%) cases were IgG-positive, and 74 (47.74%) had both IgM and IgG anti-measles antibodies. Based on these results, 35 (22.58%) children were determined to be immune, 74 (47.74%) were adjudged to have reactivated measles, 32 (20.64%) had recently contracted measles, and 14 (9.03%) were susceptible to measles infection. We found no significant association between gender, parents' education or income, frequency of facility visits, parents' knowledge of measles, and the presence of measles symptoms with IgM and IgG antibodies. The only significant association was age and IgM, being highest (22.58%) in children aged 3-5 years (P = 0.014), indicating risk of contracting measles in early childhood. This study provides an update regarding the current immunity status of children against measles infection in the post-COVID-19 era. Our study clearly indicates a need to improve measles immunization activities and strategies. The Government of Tanzania, through the Ministry of Health, should work together with international agencies such as the World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) and other stakeholders to ramp up efforts to meet the target of 95% vaccination coverage.
Indexed as
Identifiers
40455126What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.